What Are the Challenges in Targeting Prophase for Cancer Therapy?
One major challenge is the development of drug resistance. Cancer cells can acquire mutations or express efflux pumps that reduce drug efficacy. Additionally, targeting mitosis can also affect normal cells, particularly those with high turnover rates, leading to side effects like [myelosuppression]() and neuropathies. Therefore, the therapeutic window must be carefully balanced to maximize cancer cell kill while minimizing harm to normal tissues.
